Abstract:Abstract Objectives: Idiopathic inflammatory myopathies (IIM) are a group of refractory systemic autoimmune diseases with unknown pathogenesis, including dermatomyositis (DM) and polymyositis (PM). DNA methylation is an important epigenetic mechanism to regulate gene expression, which plays important roles in IIM. Integrated analysis of the whole-genome DNA methylation and gene expression profiling will provide a comprehensive understanding of the pathogenesis of IIM. Methods: We performed whole-genome DNA methylation and transcription analysis in peripheral blood of 16 DM patients, 8 PM patients and 16 normal controls (NC) using Illumina Human Methyation 450K Beadchips and Illumina Human HT-12 v4.0 Expression Beadchips. Luminex multiplex assay was used to quantify 27 cytokine/chemokine in sera of 30 DM, 16 PM and 237 NC. Genome Studio was used to identify differential DNA methylation and mRNA transcription. Integrative analysis of DNA methylome, mRNA transcriptome and serum cytokines were performed using R, Perl and Circos software. Bioinformatic analysis were performed using DAVID and R. Real-time PCR, Bisulfite pyrosequencing and immunofluorescence were used for validation. Results: Genome-wide DNA methylation analysis identified 241 differential methylated CpG sites (74 hypermethylated and 167 hypomethylated) in DM, and 500 differential methylated CpG sites (153 hypermethylated and 347 hypomethylated) in PM. Transcriptome analysis identified 540 differential expressed genes (277 upregulated and 263 downregulated ) in DM and 242 differential expressed genes (181 upregulated and 61 downregulated) in PM. Integrated analysis of DNA methylome with transcriptome suggested a significant inverse-correlation between DNA methylation and gene expression. 93 upregulated genes associated with hypomethylated CpG sites while 176 down-regulated genes related with hypermethylated CpG sites both DM and PM. Analysis of the DNA methylation and mRNA transcription data identified differential methylated CpG sites and differential expressed genes which are shared and/or unique between DM and PM. Bioinformatics analysis suggested that dysregulated genes which are shared between DM and PM participated in common biologic process, such as immune response, inflammatory response and defense response. However, differential genes which are unique in DM and PM were found to be enriched in type I interferon signaling pathway and cytokine pathway, respectively. 18 interferon related genes were upregulated and hypomethylated, IL-5 was increased and hypomethylated, PDGF-BB was decreased and hypermethylated both in DM and PM. Real-time PCR and bisulfite pyrosequencing validated 13 top changed methylation sites and genes, and showed significant correlation between DNA methylation status and gene expression in most genes. Conclusions: Our study identified differentially methylated CpG sites which have potential regulatory effects on differential gene expression in DM and PM. We also revealed dysregulated CpG sites and genes involved in common and specific biologic process in DM and PM. Type I interferon signaling pathway was significantly enrichment in DM while Cytokine signaling pathway was significantly enrichment in PM. Our observations have laid the groundwork for further diagnostic and mechanistic studies of DM and PM.

Polishing the crystal ball: mining multi-omics data in dermatomyositis

Polymyositis and Dermatomyositis Biomarkers

Using Multi-Omics Methods to Understand Dermatomyositis/polymyositis.

Pharmacological Strategies in Dermatomyositis: Current Treatments and Future Directions

A new proposal for phenotypic classification and outcome assessment of dermatomyositis based on clinical manifestations and serological testing

Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis

Multi-Omics Research Strategies for Psoriasis and Atopic Dermatitis

Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis

From traditional to targeted: the changing trajectory of therapies in dermatomyositis

Investigating genetic drivers of dermatomyositis pathogenesis using meta-analysis

Identifying Hidden Drivers Of Heterogeneous Inflammatory Skin Diseases

Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies

Integrating omics data for personalized medicine in treating psoriasis

Reveal the biomarkers and immune infiltration of dermatomyositis and explore associated diseases as well as drug molecules by bioinformatics analysis

Integrative Multiomics Approach to Skin: The Sinergy between Individualised Medicine and Futuristic Precision Skin Care?

Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

Clinical endpoints in myositis: challenges and ways forward

The interrelation of scientific, ethical, and translational challenges for precision medicine with multimodal biomarkers - A qualitative expert interview study in dermatology research

POS0851 IDENTIFICATION OF HUB GENES AND PATHWAYS IN DERMATOMYOSITIS BY BIOINFORMATICS ANALYSIS

Shared and Distinctive Transcriptomic and Proteomic Pathways in Adult and Juvenile Dermatomyositis

Genome-wide DNA Methylation and Mrna Transcription Analysis Revealed Aberrant Gene Regulation Pathways in Dermatomyositis and Polymyositis Patients